decline in AD patients, pointing to barrier-associated biomarkers as a potential tool for early detection of AD neuropathologic changes [22]. In the present study, we analyzed postmortem tissue samples from cognitively normal individuals (CNI) and individuals with AD pathology for signs of blood–b...